ARTV Stock Summary and Trading Ideas (Artiva Biotherapeutics | NASDAQ:ARTV)

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Artiva Biotherapeutics trades on the NASDAQ stock market under the symbol ARTV.

As of September 4, 2026, ARTV stock price climbed to $11.19 with 161,140 million shares trading.

ARTV has a beta of 4.24, meaning it tends to be more sensitive to market movements. ARTV has a correlation of 0.14 to the broad based SPY ETF.

ARTV has a market cap of $547.08 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that ARTV belongs to (by Net Assets): VTI, VXF, VFMO, BUSM, DFMC.

ARTV has outperformed the market in the last year with a price return of +259.8% while the SPY ETF gained +19.8%. ARTV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +45.7% and +2.4%, respectively, while the SPY returned +2.0% and +0.6%, respectively.

ARTV support price is $10.70 and resistance is $11.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARTV shares will trade within this expected range on the day.